Shree Ganesh Remedies Ltd. (SGRL): Shree Ganesh Remedies Share Price Falls 12.8% to Rs 531.95, Emerges as Top Decliner

Shree Ganesh Remedies Ltd. fell to Rs 531.95, down 12.8% today. The micro cap stock now has a market capitalisation of Rs 797.41 crore.

Shree Ganesh Remedies Share Price came under sharp pressure on 13 August 2026, falling 12.8% to Rs 531.95 from the previous close of Rs 610.05. With a market capitalisation of Rs 797.41 crore, the stock entered the spotlight as a micro cap top decliner in today’s trade. The move is notable not because the data confirms any company-specific trigger, but because the decline itself was large enough to place the stock prominently on the workflow’s price-fall screen.

For investors tracking Shree Ganesh Remedies Share Price Today, the key facts are straightforward. The stock opened at Rs 538.05, touched an intraday high of Rs 555, and fell as low as Rs 501.5 before trading at Rs 531.95. On BSE, total volume stood at 51,349 shares, with turnover at Rs 2.73 crore, showing active participation during the morning session. In Stock Market Today and Share Market Today screens, such price action often pushes a counter into Stocks in News and Top Losers Today discussions even when no separate company announcement is established by the supplied data.

From a research perspective, Univest sees three immediate areas worth tracking in this Shree Ganesh Remedies Stock News update: the depth of the day’s selling pressure, the company’s valuation versus the Pharmaceuticals & Drugs industry, and whether profitability ratios still support investor attention despite the latest share price decline.

Shree Ganesh Remedies Ltd. (SGRL) Share Price Today: Price Action Analysis

Shree Ganesh Remedies Ltd. (SGRL) traded at Rs 531.95. versus the previous close of Rs 610.05, a fall of 12.8%. The stock opened at Rs 538.05, reached Rs 555, touched Rs 501.5. Reported volume was 51,349.

Shree Ganesh Remedies Ltd. (SGRL) Fundamental Analysis

Shree Ganesh Remedies Ltd. was valued at a P/E ratio of 44.1x, a P/B ratio of 4.81x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 21.18% and ROCE of 27.51%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 13.83, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Shree Ganesh Remedies Fundamental Analysis shows a company that is not cheaply valued on simple headline multiples, yet it also carries profitability ratios that are stronger than many industry comparables. That contrast is important because today’s share price decline does not automatically erase the underlying quality signals embedded in return metrics.

At the current market price, Shree Ganesh Remedies Share Price implies a price-to-earnings ratio of 44.1 and a price-to-book ratio of 4.81. These are the most direct valuation markers available in the supplied dataset. On earnings, the company’s EPS stands at 13.83, which shows the portion of earnings attributable to each share. On net worth backing, the dividend-adjusted picture is more restrained because the dividend yield is 0, meaning the current data does not show a running yield support for the stock at this price. Even without a book value per share field, the P/B ratio indicates that the market is valuing the company at a premium to accounting net worth.

Profitability is where the numbers look firmer. ROE is 21.18% and ROCE is 27.51%, both healthy in absolute terms. ROE measures how efficiently shareholder capital is being used, while ROCE captures returns generated from the capital employed in the business. When both are above 20% and 25% respectively, they usually deserve attention in any Shree Ganesh Remedies Stock Analysis because they suggest efficient capital use rather than merely a high valuation multiple.

Market capitalisation of Rs 797.41 crore keeps the company firmly in the micro cap bracket, which matters because smaller companies often see more volatile Price Action during phases of Market Decline. That size category does not define business quality, but it does affect how quickly sentiment can shift. Overall, the supplied fundamentals present a mixed but credible backdrop: valuation is not low on headline metrics, profitability is comparatively strong, and the absence of dividend yield means investors are relying more on earnings and return ratios than on payout support. That makes sector positioning the next logical lens.

Sector and Industry Context

Shree Ganesh Remedies Ltd. (SGRL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Shree Ganesh Remedies Ltd. (SGRL) has a P/E ratio of 44.1x, which is above the benchmark median of 25.27x, a difference of +74.52%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Shree Ganesh Remedies Ltd. (SGRL) has a ROE of 21.18%, which is above the benchmark median of 10.49%, a difference of +101.91%. Shree Ganesh Remedies Ltd. (SGRL) has a ROCE of 27.51%, which is above the benchmark median of 12.97%, a difference of +112.1%.

Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Shree Ganesh Remedies operates in Healthcare, specifically Pharmaceuticals & Drugs, and the supplied same-industry benchmark helps frame whether the stock’s valuation and profitability sit above or below broader comparables. This matters because a sharp price fall often draws more attention when the company’s financial profile differs materially from its sector set.

The benchmark covers 136 companies in the same industry, giving this comparison enough breadth to be useful. Shree Ganesh Remedies Share Price currently reflects a company P/E of 44.1. That is well above the industry median P/E of 25.27, but still below the industry average P/E of 69.01. The range is extremely wide, from 3.44 to 3374.81, so the stock sits above the middle of the pack without being near the most expensive end of the spectrum. On price-to-book, the company’s 4.81 is above the benchmark median of 1.82 and the average of 2.44, indicating that the stock trades at a richer balance-sheet multiple than a large part of the same-industry universe.

Profitability comparisons are stronger. The company’s ROE of 21.18% is ahead of the benchmark median of 10.49% and also above the average of 8.09%. ROCE of 27.51% similarly exceeds the industry median of 12.97% and the average of 15.63%. That tells investors the market is assigning a higher valuation partly alongside better-than-benchmark capital efficiency. In market-cap terms, Shree Ganesh Remedies is also larger than the same-industry median of Rs 147.59 crore and above the average of Rs 490.67 crore, though still well below the largest company in the sample at Rs 3027.48 crore.

For Univest readers following Shree Ganesh Remedies Share Price News, the sector view is therefore balanced: valuation multiples are elevated versus median industry levels, but profitability metrics are also meaningfully stronger than the benchmark set. That combination often keeps a stock on investors’ radar even during sharp one-day declines.

Peer Comparison

Shree Ganesh Remedies Ltd. (SGRL) has a P/E ratio of 44.1x compared with the displayed peer median of 44.25x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 21.18% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 27.51% versus the displayed peer median of 12.97%, providing a capital-efficiency comparison. Shree Ganesh Remedies Ltd. (SGRL) has a market capitalisation of Rs 797.41 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Peer data suggests Shree Ganesh Remedies sits in an interesting middle zone: its valuation is neither the cheapest nor the most expensive among comparable pharmaceuticals names, while its return ratios are stronger than several larger peers. That makes today’s price fall relevant for relative valuation watchers.

Against the supplied peer set, Shree Ganesh Remedies Share Price carries a P/E of 44.1, which is close to Ind-Swift Laboratories at 44.25 and NGL Fine-Chem at 43.8. It remains below Beta Drugs at 68.39 and far below Sai Parenteral’s at 171.25, while standing above Hester Biosciences at 15.32. On price-to-book, Shree Ganesh Remedies at 4.81 is richer than Hikal at 2.2, Sai Parenteral’s at 3.13 and Ind-Swift Laboratories at 1.76, but lower than Beta Drugs at 10.82, Panacea Biotec at 8.59, NGL Fine-Chem at 6.4 and Sakar Healthcare at 6.22.

The profitability picture is more supportive. ROE at 21.18% is ahead of Beta Drugs at 18.65%, Hikal at 15.22%, Sai Parenteral’s at 13.9%, Solara Active Pharma Sciences at 17.23%, Sakar Healthcare at 11.88% and Hester Biosciences at 16.17%. Only NGL Fine-Chem, at 27.9%, is clearly stronger among the peers that also carry a disclosed P/E. ROCE at 27.51% also compares well, exceeding Beta Drugs at 22.17%, Hikal at 16.15%, Sai Parenteral’s at 12.97%, Ind-Swift Laboratories at 8.31%, Panacea Biotec at 5.36%, Solara at 15.34%, Sakar at 13.16% and Hester at 14.12%, while trailing NGL Fine-Chem at 33.91%.

Size is the clear limitation. With a market cap of Rs 797.41 crore, the company is smaller than all listed peers in the supplied set, each of which ranges from Rs 2112.08 crore to Rs 3027.48 crore. Univest reads that as a reminder that stronger return ratios do not eliminate the higher volatility often seen in smaller market-cap names.

Why Investors Are Watching Shree Ganesh Remedies

Shree Ganesh Remedies Share Price has become a closely watched counter today because the fall was both sharp and visible on BSE screens. A 12.8% decline in one session is enough to push a stock into Top Losers Today and Stocks Falling Today conversations, especially when it comes from a micro cap name in the Healthcare space. Beyond the raw fall, the stock also presents a valuation-versus-profitability contrast that market participants often monitor closely. Its P/E and P/B ratios are above sector medians, yet ROE and ROCE remain materially stronger than the same-industry benchmark. That combination can keep the stock in active discussion across intraday traders, longer-horizon trackers, and investors following Shree Ganesh Remedies Latest News, price action and sector positioning.

• Price action: The stock fell Rs 78.1 to Rs 531.95 from Rs 610.05, after trading between Rs 555 and Rs 501.5.
• Volume participation: BSE volume stood at 51,349 shares with turnover of Rs 2.73 crore, confirming active trading interest.
• Fundamental context: P/E is 44.1 and P/B is 4.81, while ROE is 21.18% and ROCE is 27.51%.
• Sector positioning: ROE and ROCE are above same-industry medians, even though valuation multiples are also above median levels.
• Market-cap profile: At Rs 797.41 crore, the stock remains a micro cap, which can amplify volatility during sessions marked by selling pressure.

What investors may monitor next is whether Shree Ganesh Remedies Share Price stabilises after testing Rs 501.5 on the downside, and whether the stock continues to attract notable Trading Volume relative to its size. They may also watch whether valuation resets faster than profitability perception changes. Univest would frame this as a stock where the one-day decline is confirmed by data, while the broader interpretation still depends on how future price action interacts with its return profile and industry valuation context.

About Shree Ganesh Remedies

Shree Ganesh Remedies Ltd. is classified within the Healthcare sector and the Pharmaceuticals & Drugs industry. Even without a longer supplied company profile, that industry placement provides useful context for how investors read the stock. Companies in this space are typically analysed through a combination of valuation multiples, return ratios, and market-cap positioning because earnings quality and capital efficiency often matter as much as headline growth expectations.

In the market context supplied here, Shree Ganesh Remedies is a micro cap pharmaceutical company with a market capitalisation of Rs 797.41 crore. That places it above the same-industry median market capitalisation of Rs 147.59 crore and the industry average of Rs 490.67 crore, but still below larger listed peers such as Dishman Carbogen Amcis, Beta Drugs and Hikal. This middle positioning is important for Shree Ganesh Remedies Share Price because it combines some scale within its industry bracket with the sharper day-to-day volatility that smaller listed counters can still display.

The financial profile shown in the dataset also gives a sketch of how the market currently views the business. A P/E of 44.1 and P/B of 4.81 indicate that the stock is not priced like a distressed counter, while ROE of 21.18% and ROCE of 27.51% show that the business has been generating comparatively solid returns on capital. For readers following Shree Ganesh Remedies Company News and Shree Ganesh Remedies Earnings trends, those are the main verified operating signals visible in the supplied data snapshot.

Track Shree Ganesh Remedies Share Price on Univest

Use Shree Ganesh Remedies Ltd. (SGRL) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors who want to follow Shree Ganesh Remedies Share Price more closely can use Univest to monitor live price moves, daily percentage change, market capitalisation, valuation ratios and sector context in one place. For active market participants, that helps connect intraday price action with broader stock analysis rather than viewing a single-day decline in isolation.

On Univest, users can track Shree Ganesh Remedies Share Price Today alongside metrics such as P/E ratio, P/B ratio, ROE, ROCE, EPS, dividend yield and 52-week levels when available. The platform also helps place a stock within its sector and peer group so investors can compare profitability, valuation and market-cap positioning. For readers scanning Stock Updates, NSE News, BSE News and Market News, that wider context often matters as much as the latest price fall itself.

Frequently Asked Questions

What is the latest Shree Ganesh Remedies Share Price Today?

Ans. Shree Ganesh Remedies Share Price Today was Rs 531.95 at the time of this update. The stock was down 12.8% from the previous close of Rs 610.05, making it one of the notable top decliners in today’s market action.

Why is Shree Ganesh Remedies stock falling today?

Ans. The supplied data confirms that the stock fell 12.8% in the session, but it does not establish a company-specific catalyst. What is verified is the price fall from Rs 610.05 to Rs 531.95 and the broad intraday weakness.

What were the day high and day low for Shree Ganesh Remedies shares?

Ans. During the session, Shree Ganesh Remedies traded between an intraday high of Rs 555 and an intraday low of Rs 501.5. The stock opened at Rs 538.05, showing weakness early and then extending losses during trading.

How much market capitalisation does Shree Ganesh Remedies have?

Ans. Shree Ganesh Remedies had a market capitalisation of Rs 797.41 crore in the supplied data snapshot. That places it in the micro cap category and above the same-industry median market capitalisation of Rs 147.59 crore.

Is Shree Ganesh Remedies expensive on P/E compared with its industry?

Ans. The company’s P/E ratio is 44.1. That is above the same-industry median P/E of 25.27, but below the same-industry average of 69.01, showing that valuation is elevated versus the median without being the highest in the sample.

How does Shree Ganesh Remedies compare on profitability?

Ans. The stock’s ROE is 21.18% and ROCE is 27.51%. Both are higher than the same-industry median figures of 10.49% for ROE and 12.97% for ROCE, indicating stronger profitability than many benchmark companies.

What is the P/B ratio of Shree Ganesh Remedies?

Ans. Shree Ganesh Remedies has a price-to-book ratio of 4.81. That is above the same-industry median of 1.82 and the average of 2.44, suggesting the stock trades at a richer balance-sheet multiple than many peers.

What are the EPS and dividend yield of Shree Ganesh Remedies?

Ans. The supplied data shows EPS of 13.83 and a dividend yield of 0. EPS reflects earnings attributable to each share, while the current dividend yield indicates there is no yield support visible in this data snapshot.

How active was trading volume in Shree Ganesh Remedies on BSE?

Ans. The stock recorded BSE volume of 51,349 shares, with total volume also at 51,349 shares and turnover at Rs 2.73 crore. That confirms active participation during the session in which the share price declined sharply.

Which sector and industry does Shree Ganesh Remedies belong to?

Ans. Shree Ganesh Remedies belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The benchmark comparison in this article uses 136 companies from the same industry, helping place valuation and profitability in context.